Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)

Launched by MỸ ĐỨC HOSPITAL · Apr 16, 2024

Keywords

ClinConnect Summary

The LETSACT trial is studying two different methods of preparing the uterus for frozen embryo transfer in women who have irregular menstrual cycles. The main question is whether using a medication called letrozole, which helps stimulate egg development, leads to a higher chance of having a healthy baby compared to the more traditional method called the artificial cycle. Women aged 18 to 42 with irregular cycles and who are preparing for the transfer of one embryo may be eligible to participate.

If you join the trial, you will be randomly assigned to one of two groups. One group will take letrozole along with progesterone to support the uterus, while the other group will take a different hormone treatment. Throughout the study, researchers will monitor and compare the success rates of both methods to see which one results in more live births. It's important to note that certain conditions, such as specific health issues related to the uterus or previous pregnancy problems, may prevent some women from participating.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Aged between 18 - 42.
• • Irregular menstrual cycle (\< 21 days or \> 35 days or \< 8 cycles/years).
• • Indicated for endometrial preparation.
• • Transfer of only one blastocyst.
• • Not participating in any other trials.
• Exclusion Criteria:
• • Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone
• • Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.
• • Ovarian cysts that are unrelated to the oocyte pick-up.
• • Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations.
• • Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.
• • Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate (according to ASRM 2021).
• • Untreated hydrosalpinx.